PHARMACOLOGICAL ASPECTS OF HYPOTHALAMUS / PITUITARY & ADRENAL DISORDERS

Zulhilmi Zainal
Mind Map by , created over 5 years ago

Mind Map on PHARMACOLOGICAL ASPECTS OF HYPOTHALAMUS / PITUITARY & ADRENAL DISORDERS, created by Zulhilmi Zainal on 04/14/2014.

1052
0
0
Tags No tags specified
Zulhilmi Zainal
Created by Zulhilmi Zainal over 5 years ago
GCSE AQA Biology 3 Kidneys & Homeostasis
Lilac Potato
Camera Angles
saradevine97
chemistry: c2
kristy baker
Procedimientos Operacionales
Adriana Forero
Information security and data protection
хомяк убийца
CHEMISTRY C1 7
x_clairey_x
Present Simple vs. Present Continuous
Marek Mazur
B3- Science. Cells, Genes and Enzymes.
MissChurro
AQA Physics P1 Quiz
Bella Statham
Input, output and storage devices
Mr A Esch
PHARMACOLOGICAL ASPECTS OF HYPOTHALAMUS / PITUITARY & ADRENAL DISORDERS
1 physiology
2 Growth Hormone
2.1 somatropin,somatrem(synthetic analog)
2.2 To improve growth in children with GH deficiency
2.3 Adverse
2.3.1 Carpal tunnel syndrome, hyperglycemia
2.4 Somatostatin
2.4.1 Somatotropin releasing inhibiting hormone
2.4.2 Synthetic
2.4.2.1 1 Octreotide 2 Pegvisomant
2.4.2.2 uses
2.4.2.2.1 Acromegaly. Carcinoid tumors. Pancreatic tumors
2.4.2.3 Adverse
2.4.2.3.1 sludge(gallstone)
3 ERGOT DERIVATIVES (DOPAMINE AGONIST (D2)
3.1 Decrease prolactin
3.2 Bromocriptine
3.3 USES
3.3.1 Hyperprolactinemia
3.3.2 Parkinsonism
3.4 effecs
3.4.1 syncope,postural hypotension, psychosis
4 Vassopressin
4.1 ADH
4.2 Uses
4.2.1 Neurogenic DI(pituitary)(central DI)
4.2.2 Nephrogenic DI(impaired renal response to AVP)
4.2.3 Constrict blood vessel
4.3 Adverse
4.3.1 coronary vasospasm
4.3.2 uterine contraction
5 Desmopressin
5.1 selective (V2) agonist
5.2 Uses
5.2.1 DI(Central,pituitary)(DOC) Bedwetting(children)
6 Adenocorticosteroids
6.1 MAGIC drug
6.1.1 Synthesis
6.1.2 uses
6.1.2.1 ALL Disease usable
6.1.2.1.1 Neurologic diseases
6.1.2.1.2 Pulmonary diseases
6.1.2.1.3 Renal disease
6.2 Immunosuppression
6.3 TOXICITY
6.3.1 Acute withdrawal
6.3.1.1 cerebral edema
6.3.1.2 fever, myalgia
6.3.2 Prolonged usage
6.3.2.1 fluid/lyte disturbances, hypertension, hyperglycemia, glycosuria
6.3.2.2 peptic ulcers, osteoporosis (direct inhibition of osteoblasts) myopathy, cataracts